However, HDAC inhibition remains an interesting mechanism of action in MM, with in vitro demonstration of its efficacy, although there is room for improvement, as targeting this sole pathway does not lead to the expected results in clinical practice. This evidence concerns the gene HDAC9 and Miyoshi myopathy.